---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-034811"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:17:28.561085+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PMGC subsidiary Northstrive gets FDA support for IND submission of EL-22 with GLP-1 for obesity

## Summary
- FDA agreed pharmacology studies support EL-22 activity and nonclinical studies appear adequate for safety/activity in overweight/obese humans.
- Phase 1 and completed nonclinical data deemed adequate to allow initiation of a proposed Phase 2 clinical trial.
- Northstrive aims to file IND in 2025 and start Phase 2 trial evaluating EL-22 combined with GLP-1 receptor agonists.
- EL-22 is a patent-pending engineered probiotic designed to express myostatin, targeting muscle preservation during weight loss.
- Preclinical data in mdx mice showed significant physiological and functional improvements; Phase 1 in South Korea showed good tolerability.

## SEC filing metadata
- accession: 0001213900-25-034811
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390025034811/0001213900-25-034811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390025034811/ea0239158-8k_pmgc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-034811
- JSON: https://secwatch.observer/filing/0001213900-25-034811.json
- Plain text: https://secwatch.observer/filing/0001213900-25-034811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.